tbuckley/cabot-search huggingface dataset:
A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.
Authors: Frederic Pouliot, Peter Carroll, Stephan Probst, Kenneth J. Pienta, Steven P. Rowe, Lawrence Saperstein, Barry Siegel, Akash Patnaik, Mark A. Preston, Ajjai Shivaram Alva, Michael A. Gorin, Michael J. Morris
Journal: Journal of Clinical Oncology (2020)

9 Background: Current imaging modalities are suboptimal for the initial staging of men at risk of harboring occult metastatic prostate cancer (PCa). PSMA-based imaging is considered highly promising for PCa detection. 18 F-DCFPyL is a novel PSMA-targeted radiopharmaceutical for positron emission tomography (PET) that may be useful in staging of pts with high risk PCa. The diagnostic performance of 18 F-DCFPyL regarding regional and distant metastases has been previously reported. Here we report on detection rates and the resulting impact 18 F-DCFPyL may have on staging of pts with high risk PCa. Methods: 18 F-DCFPyL PET/CT was evaluated in 252 men with high-risk PCa who were planned for radical prostatectomy with lymphadenectomy (RP-PLND). 9 mCi (333 MBq) of 18 F-DCFPyL was administered 1-2 hours prior to PET/CT. Based on TNM staging, 18 F-DCFPyL PET/CT detection rates including lesion counts were systematically analyzed: prostatic (T), pelvic LN (N), extra-pelvic LN (M1a), bone (M1b) &amp; other visceral organs/soft tissue (M1c). Three central, blinded, and independent readers evaluated the 18 F-DCFPyL scans. Results: At study entry, 97% and 99% of all evaluable pts had no known nodal or metastatic disease, respectively, based on standard cross-sectional imaging. Of these, 18 F-DCFPyL PET/CT staged 37 (14.7%) pts with N1 disease and 27 (10.7%) pts with M1 disease (1 [0.4%] M1a, 23 [9.1%] M1b, and 3 [1.2%] M1c). In total, 56 (22%) of patients were upstaged to N1 or M1 disease by 18 F-DCFPyL. The positive predictive value of 18 F-DCFPyL based on histopathologic validation for pelvic LNs was 86.7% (95% CI: 70, 95). Only one patient in Cohort A underwent a biopsy of their 18 F-DCFPyL detected M1 finding; histopathology confirmed the metastatic lesion in the spine to be a true positive. Conclusions: A total of 22% of pts with high-risk PCa planned for RP-PLND had regional or distant metastatic lesions detected on 18 F-DCFPyL PET/CT. These results suggest the potential utility of 18 F-DCFPyL PET/CT in the staging of men with newly diagnosed high risk PCa to develop optimized treatment paradigms. Clinical trial information: NCT02981368.
Effect of early parenteral nutrition during paediatric critical illness on DNA methylation as a potential mediator of impaired neurocognitive development: a pre-planned secondary analysis of the PEPaNIC international randomised controlled trial
Authors: Fabian Güiza, Ilse Vanhorebeek, Sören Verstraete, Ines Verlinden, Inge Derese, Catherine Ingels, Karolijn Dulfer, Sascha C Verbruggen, Gonzalo Garcia Guerra, Koen F Joosten, Pieter J Wouters, Greet Van den Berghe
Journal: The Lancet Respiratory Medicine (2020)
Multi-Center Observational Study on the Diagnosis of Non-Small Cell Lung Cancer Bone Metastasis and the Efficacy and Safety of Bisphosphates Treatment (C-TONG 0801)
Authors: Y. Wu, Z. Li, C. Zhou, L. Shun, Y. Zhang, M. Hou, W. Liu, J. Wang, G. Chen, Y. Zhou
Journal: Annals of Oncology (2012)
Infant rhinorrhea and watery eyes in the absence of a cold associated with increased heart rate variability among girls
Authors: Laura Conrad, Natalie Buchinsky, Luis Acosta, J. David Nugent, Khalil Savary, David Merle, Frederica Perera, Virginia Rauh, Rachel Miller, Julie Herbstman, Beatrice Beebe, Michael Myers, William Fifer, Matthew Perzanowski
Journal: Journal of Allergy and Clinical Immunology (2020)
Inflammation‐Induced Long Intergenic Noncoding RNA (LINC00665) Increases Malignancy Through Activating the Double‐Stranded RNA–Activated Protein Kinase/Nuclear Factor Kappa B Pathway in Hepatocellular Carcinoma
Authors: Jie Ding, Jingjing Zhao, Lin Huan, Yizhe Liu, Yejun Qiao, Zhen Wang, Zhiao Chen, Shenglin Huang, Yingjun Zhao, Xianghuo He
Journal: Hepatology (2020)

Background and Aims The nuclear factor kappa B (NF‐κB) signaling pathway is important for linking inflammation and tumorigenesis. Here, we characterized an NF‐κB signaling activation–induced long intergenic noncoding (LINC) RNA in hepatocellular carcinoma (HCC), LINC00665, that contributes to the enhanced cell proliferation of HCC cells both in vitro and in vivo . Approach and Results LINC00665 physically interacts with the double‐stranded RNA (dsRNA)‐activated protein kinase (PKR), enhances its activation, and maintains its protein stability by blocking ubiquitin/proteasome‐dependent degradation, resulting in a positive feedback regulation of NF‐κB signaling in HCC cells. Notably, patients with HCC and higher LINC00665 have poorer outcomes in the clinic. Conclusions Our findings indicate that LINC00665 is involved in the NF‐κB signaling activation in HCC cells and that the inflammatory LINC00665/PKR/NF‐κB loop plays important oncogenic roles in hepatic cancer progression and may be a potential therapeutic target.
Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.
Authors: Sara Elena Rebuzzi, Sebastiano Buti, Marco Maruzzo, Ugo De Giorgi, Andrea Sbrana, Paolo Andrea Zucali, Emanuela Fantinel, Giuseppe Procopio, Sara Merler, Lucia Fratino, Cinzia Baldessari, Riccardo Ricotta, Francesco Massari, Giuseppe Luigi Banna, Mariella Soraru', Matteo Santoni, Alessio Cortellini, Melissa Bersanelli, Alessio Signori, Giuseppe Fornarini
Journal: Journal of Clinical Oncology (2020)

e17081 Background: Biomarkers to select mRCC patients most likely to benefit to immunotherapy are needed. The retrospective multicentre Meet-URO-15 study evaluated the prognostic role of peripheral blood cells in mRCC patients treated with Nivolumab. Methods: Complete blood count was assessed at the first four cycles of Nivolumab. The primary endpoint was median overall survival (mOS) according to bNLR. NLR was defined as neutrophil / lymphocyte (cutoff = 3) and ΔNLR the difference between NLR at 2 nd cycle and bNLR (median as cutoff = 1.1). Results: From October 2015 to October 2019, 470 patients started Nivolumab as 2 nd (67%), 3 rd (22%) and &gt; 3 rd (11%) line. Median age was 66 years, 71% were male and 83% had clear cell histology. Baseline IMDC group was favorable in 25%, intermediate in 63% and poor in 12%. Lymph-nodes, visceral and bone metastases were present in 54%, 91% and 36%. mOS and progression-free survival (PFS) were 34.8 and 7.5 months. Overall response rate (ORR) and disease control rate (DCR) were 30% and 61%. bNLR was available in 404 patients: bNLR &lt; 3 (54%) correlated with statistically significant longer PFS [11.4 vs 5.4 months; HR 1.69 (1.33-2.15)] and OS [46.2 vs 17.2 months; HR 2.37 (1.72-3.26)] (both p&lt; 0.001), with similar ORR (35% vs 30%, p= 0.28) but higher DCR (71% vs 52%, p&lt; 0.001). ΔNLR was available in 360 patients: ΔNLR &lt; 1.1 (73%) correlated with a statistically significant improvement of PFS [11.2 vs 4.9 months; HR 1.53 (1.16-2.03), p= 0.03], OS [Not Reached vs 19.7 months; HR 1.83 (1.28-2.61), p= 0.001], ORR (37% vs 23%, p= 0.011) and DCR (68% vs 53%, p= 0.008). Multivariate analyses adjusted for IMDC group, line of therapy and metastatic sites, confirmed the statistically significant correlation of bNLR and ΔNLR with OS, PFS and DCR. Conclusions: Our study showed the statistically significant correlation of lower bNLR and early ΔNLR with longer OS, PFS and higher DCR in mRCC patients treated with Nivolumab.
Biological Versus Chronological Aging
Authors: Magda R. Hamczyk, Rosa M. Nevado, Ana Barettino, Valentín Fuster, Vicente Andrés
Journal: Journal of the American College of Cardiology (2020)

Aging is the main risk factor for vascular disease and ensuing cardiovascular and cerebrovascular events, the leading causes of death worldwide. In a progressively aging population, it is essential to develop early-life biomarkers that efficiently identify individuals who are at high risk of developing accelerated vascular damage, with the ultimate goal of improving primary prevention and reducing the health care and socioeconomic impact of age-related cardiovascular disease. Studies in experimental models and humans have identified 9 highly interconnected hallmark processes driving mammalian aging. However, strategies to extend health span and life span require understanding of interindividual differences in age-dependent functional decline, known as biological aging. This review summarizes the current knowledge on biological age biomarkers, factors influencing biological aging, and antiaging interventions, with a focus on vascular aspects of the aging process and its cardiovascular disease related manifestations.
GEFITINIB for Non-Small Cell Lung Cancer (NSCLC) with Minor EGFR Mutations: A Retrospective Study from the North East Japan Study Group (NEJ)
Authors: S. Watanabe, H. Yoshizawa, M. Maemondo, A. Inoue, S. Sugawara, H. Isobe, M. Harada, Y. Ishii, K. Hagiwara, K. Kobayashi
Journal: Annals of Oncology (2012)
Phase II study of cabazitaxel (CAB) plus enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC).
Authors: Julie Nicole Graff, Heather H. Cheng, Jacqueline Vuky, Joshi J. Alumkal, Dustin Kreitner, Delia Petreaca, Petros Grivas, Michael Thomas Schweizer, Celestia S. Higano, Yiyi Chen, Evan Y. Yu, Tomasz M. Beer
Journal: Journal of Clinical Oncology (2020)

86 Background: There are six agents that improve survival in mCRPC, each administered as a single agent. Combinations of agents with distinct mechanisms of action have the potential to improve outcomes. Methods: We performed a multi-institution phase I/II study to examine safety and efficacy of CAB plus ENZ with mandatory granulocyte-colony stimulating factor support in mCRPC. Results: A sample size of 3 to 12 subjects for the phase I portion and 33 for the phase II portion provided 82% power to detect PSA response rate (decrease ≥90%) of 50% compared to the null hypothesis of 24%. The main eligibility criteria allowed prior abiraterone/prednisone (AAP) and docetaxel (in the metastatic hormone sensitive setting). Baseline characteristics: median age 69 years (47 - 82), median PSA 20.2 ng/dl (0.2 - 966.3); 7 subjects had visceral disease, 10 received prior AAP, and 8 received prior docetaxel. In the phase I portion, there were no dose limiting toxicities using CAB 25 mg/m 2 IV Q3wks up to 10 cycles and ENZ 160 mg PO QD, hence this dosing was used for the phase II portion. 33 men with mCRPC were treated with CAB plus ENZ in the phase II arm. PSA response rates are listed in Table. Prior exposure to AAP decreased PSA response, but subjects who had prior AAP also had higher pre-treatment PSA. There were no treatment related deaths. Dose reduction of CAB to 20 mg/m 2 was needed in 7 subjects. Over the course of the study, 14 Grade 3 adverse events occurred that were deemed possibly related to treatment: fatigue (n=2, 6%), febrile neutropenia (n=2, 6%), leukopenia (n=2, 6%), thrombocytopenia (n=2, 6%), anemia (n=1, 3%), hypertension (n=1, 3%), leukocytosis (n=2, 6%), fracture (n=1, 3%), failure to thrive (n=1, 3%). Conclusions: CAB plus ENZ was tolerable and associated with promising anti-tumor activity, particularly in abiraterone-naïve subjects. Further evaluation of this regimen is warranted. This project was managed by the Prostate Cancer Clinical Trials Consortium and funded by Astellas Inc. and Sanofi. Clinical trial information: NCT02522715. [Table: see text]
Development of a framework for minimum and optimal safety and quality standards for hemodialysis and peritoneal dialysis
Authors: Laura Sola, Nathan W. Levin, David W. Johnson, Roberto Pecoits-Filho, Harith M. Aljubori, Yuqing Chen, Stefaan Claus, Allan Collins, Brett Cullis, John Feehally, Paul N. Harden, Mohamed H. Hassan, Fuad Ibhais, Kamyar Kalantar-Zadeh, Adeera Levin, Abdulkarim Saleh, Daneil Schneditz, Irma Tchokhonelidze, Rumeyza Turan Kazancioglu, Ahmed Twahir, Robert Walker, Anthony J.O. Were, Xueqing Yu, Fredric O. Finkelstein
Journal: Kidney International Supplements (2020)
Improving IMDC criteria in patients with metastatic renal cell carcinoma through the addition of initial metastatic site in bone, brain, and liver.
Authors: Vincenzo Di Nunno, Francesco Massari, Annalisa Guida, Carolina Alves Costa Silva, Lisa Derosa, Veronica Mollica, Emeline Colomba, Bernard Escudier, Laurence Albiges
Journal: Journal of Clinical Oncology (2020)

754 Background: IMDC criteria are largely adopted to estimate patient prognosis. In a retrospective study we assessed that the addition of first site of metastases in brain bone and liver (bbl) metastases as variable improves prognostic stratification of patients (pts) with metastatic renal cell carcinoma (mRCC). We performed a validation study in an external cohort of patients with mRCC. Methods: All consecutive mRCC pts treated at a single institute and included in the local IGReCC database. All pts received at least one line of targeted therapy or ICIs. Primary outcome was OS from first line start. Univariate and multivariate analysis (cox regression model) were performed. Bootstrap was also carried out for validation. Results: 1073 mRCC pts were analysed (808 with known IMDC score). Of 13 initial variables considered for prognostic model, the presence of bbl as first site/s of metastases plus the 6 variables included in IMDC resulted as statistically significant factors associated with OS (table). By including this new parameter we developed a 7-variables based score (IMDC-7). Patients with 0, 1-2 and≥3 positive variable/s were considered as good, intermediate and poor risk patients respectively. 56 (22%) pts moved from good (IMDC) to intermediate (IMDC-7) and 66 (15.4%) pts moved from intermediate (IMDC) to poor (IMDC-7) group (table). Final bias corrected concordance c-index was 0.69 and 0.71 in overall cohort and in pts treated with ICI (n=241). Conclusions: The addition of bbl primary metastases to the others IMDC variables improves prognostic predictive power of the model.[Table: see text]
Association of salvage cryoablation with decreased utilization of androgen deprivation therapy for recurrent prostate cancer after radiotherapy.
Authors: J Kellogg Parsons, Brittney Cotta, Brent Rose, James Don Murphy, Stephen T. Ryan
Journal: Journal of Clinical Oncology (2020)

358 Background: Cryoablation is an established treatment for recurrent prostate cancer after primary radiotherapy, but outcomes data are mostly limited to uncontrolled case series. We assessed salvage cryoablation efficacy with a comparative analysis in a large national cohort. Methods: Patients with clinically localized prostate cancer treated with primary radiotherapy from 2000 to 2015 were identified in the Veterans Affairs Informatics and Computing Infrastructure (VINCI) dataset. Prostate-specific antigen (PSA) recurrence was defined as nadir + 2 ng/mL. Inclusion criteria included availability of serial PSA measures for ≥ 3 years after completion of radiotherapy and PSA &lt; 10 ng/mL at recurrence. Salvage cryotherapy was identified with procedure- and fee-based billing codes. Chi square and Wilcoxon analysis was utilized for descriptive statistics; and Kaplan Meier analyses for time to androgen deprivation therapy (ADT). Results: Among 35,502 patients who underwent primary radiotherapy, 4,391 (12.3%) developed biochemical recurrence a median (IQR) of 4.5 (2.7, 6.9) years after treatment. Of these, 3889 (88.9%) had PSA &lt; 10 ng/mL at time of recurrence, of whom 95 (2.4%) underwent salvage cryoablation. Cryoablation patients were younger at initial diagnosis (60 years versus 65 years, p &lt; 0.01); had a lower pre-treatment PSA (6.6 ng/mL versus 7.8 ng/mL, p &lt; 0.01); and had a lower PSA nadir (0.04 ng/mL versus 0.19 ng/mL, p&lt;0.01). There were no between-group differences for clinical stage at initial diagnosis (p = 0.22) or African American prevalence (34.7% versus 29%, p =0.27). After recurrence, median (IQR) follow-up for those who did and did not receive cryoablation was 9.1 (7.2, 9.11) and 8.1 (5.4, 10.9) years, respectively. Cryoablation patients were less likely to receive ADT (40% versus 55%, p &lt; 0.01); and, among those who did, time to ADT from recurrence was significantly longer compared to those who did not receive cryoablation (15.5 months versus 5.8 months, p&lt;0.01). Conclusions: Salvage cryoablation is associated with decreased utilization of ADT in patients with biochemical recurrence after radiation.
Real-World Practices and Perceptions Regarding Shared Decision-Making and Patients’ Quality of Life among Allergy and Dermatology Teams in Two Large US Healthcare Systems
Authors: Christopher Codispoti, Giselle Mosnaim, Peter Lio, Kristina Fajardo, Laura Simone, James Mateka, Jeff Carter, Tamar Sapir
Journal: Journal of Allergy and Clinical Immunology (2020)
Real-life experience with nivolumab and pembrolizumab in patients(pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety analysis at the University Hospital Zurich
Authors: D Akhoundova Sanoyan, A. Siebenhüner, R. Delaloye, L. Bankel, T.D.L. Paulino, A. Curioni
Journal: Annals of Oncology (2017)
Fabrication of polyphenol-incorporated anti-inflammatory hydrogel via high-affinity enzymatic crosslinking for wet tissue adhesion
Authors: Su-Hwan Kim, Kyungmin Kim, Beom Seok Kim, Young-Hyeon An, Uk-Jae Lee, Sang-Hyuk Lee, Seunghyun L. Kim, Byung-Gee Kim, Nathaniel S. Hwang
Journal: Biomaterials (2020)
Molecular characteristics of renal cell carcinoma (RCC) risk groups from JAVELIN Renal 101.
Authors: Toni K. Choueiri, John B. A. G. Haanen, James M. G. Larkin, Brian I. Rini, Laurence Albiges, Robert J. Motzer, Alessandra di Pietro, Xinmeng Jasmine Mu, Keith A. Ching, Subramanian Hariharan, Paul B. Robbins
Journal: Journal of Clinical Oncology (2020)

744 Background: The phase 3 JAVELIN Renal 101 trial in patients (pts) with advanced RCC demonstrated a progression-free survival (PFS) benefit and higher objective response rate (ORR) with avelumab + axitinib (A+Ax) vs sunitinib (S) (Motzer NEJM 2019). PFS and ORR favored A+Ax in all MSKCC risk groups, but median PFS varied. Here, we report results from analyses of baseline tumor samples to define molecular characteristics underlying risk group classifications. Methods: Nephrectomy or tumor samples from pts enrolled in the study were characterized by immunohistochemistry (CD8 and PD-L1), whole exome sequencing, or gene expression profiling (n = 705–850). Gene expression signatures (GES), pathway activation status, and mutational profiles were examined in relation to MSKCC risk groups. Results: Of the 886 total pts enrolled, 23%, 66%, and 11% had favorable (F), intermediate (I), or poor (P) MSKCC risk factors at baseline. In the F, I, and P groups, the ORR was 66%/38%, 50%/24%, and 31%/9%; median PFS was NR/16.7 mo, 13.3 mo/7.9 mo, and 5.6 mo/2.8 mo for the A+Ax/S arms, respectively. Neither the presence of PD-L1+ immune cells nor CD8+ cells differentiated the subgroups; however, the presence of PD-L1+ tumor cells was highest in the P group (p=0.0159). When compared to the I and P groups, the F group was enriched for NOTCH2 mutations (p=0.0002), displayed high FLT1 expression (p=0.007), and showed a trend favoring angiogenesis GES (JAVELIN Renal 101 and IMmotion150). The I group displayed few distinguishing characteristics (low neutrophil GES [p=0.02] and elevated homeobox gene expression [p=0.00052]). Relative to the F group, the P group showed higher cell cycle gene expression (p=0.0057) and PTEN mutation frequency, wild-type NOTCH2 genotype, elevated IMmotion150 Myeloid inflamed GES (p=0.0024), and macrophage-specific GES (p=0.0327), as well as GES for TH2 (p=0.0002), hypoxia (p=0.0199), glycolysis (p=0.0066), and the lowest expression of a dendritic cell GES (p=0.0209). Conclusions: In advanced RCC patients, biological differences within each MSKCC risk category may impact response to treatment and may help explain why these groups perform differently. Clinical trial information: NCT02684006.
Concurrent durvalumab and radiation therapy followed by adjuvant durvalumab in patients with locally advanced urothelial cancer of bladder (DUART): Btcrc-GU15-023.
Authors: Monika Joshi, Leonard Tuanquin, Matthew Kaag, Deepak Kilari, Sheldon L. Holder, Hamid Emamekhoo, Alexander Sankin, Suzanne B Merrill, David DeGraff, Joshua Warrick, Hong Zheng, Ralph J. Hauke, Benjamin Adam Gartrell, Mark N. Stein, Yousef Zakharia, Joseph J. Drabick
Journal: Journal of Clinical Oncology (2020)

513 Background: Bladder cancer (BC) patients (pts) who are cisplatin ineligible/unfit for surgery, unresectable have limited treatment options. In this study, we investigate if the combination of radiation therapy (RT) and checkpoint inhibitor, durvalumab (durva) is safe and effective in these pts. Our results from phase (ph) Ib suggested that the combination was safe. Here we present the response rate post durvaRT and updated treatment related adverse events (TRAEs) amongst our evaluable pts in ph II. Methods: This is a single arm ph Ib-II study for T2-4 N0-2 M0 pts. The ph II primary endpoints a) PFS rate at 1 yr b) disease control rate (DCR); secondary endpoints were a) CR post durvaRT b) PFS c) OS. Pts were treated with durva (1500mg) Q4 wks x2 doses along with definitive RT (64.8Gy, 36 fractions over 7 wks) to the bladder and involved nodes followed by adjuvant durva Q4 wks x 1 yr. Response was evaluated with CT scan and cystoscopy+biopsy post durvaRT. We anticipated that durvaRT followed by durva would increase PFS at 1 yr from 50% to 75% when compared to RT; we assumed DCR of about 75%. A total of 26 pts were needed to reach a statistical power of at least 80% at one-sided alpha of 5% and to allow for 10% drop out rate. Results: Total N = 26 patients (male 19; female 7, median age 74yr). At the time of data cut off, 21/26 pts were evaluable for response post durvaRT. Post completion of durvaRT time point, clinical CR was seen in 15/21 pts (71.4%); PR 1/21 pts (4.7%); SD 4/21 (19%); PD 1/21 (4.7%). DCR was seen in 20/21 pts (95%) post durvaRT. Median follow up from D1 to last follow up was 6.1 mos. Grade ≥ 3 TRAE amongst 26 pts: anemia (1/26), lipase/amylase (1/26), immune nephritis (1/26), dyspnea (gr 4, copd/immune), fatigue (1/26), lymphopenia (6/26). Other TRAEs: Fatigue was the most common TRAE (16/26); UTI (5/26); cystitis (3/26). No fatal TRAEs were observed. Conclusions: DurvaRT demonstrated promising efficacy with clinical CR of 71.4% and DCR of 95% in unresectable, cisplatin ineligible locally advanced BC. It was generally well tolerated. Ph II study has completed accrual and longer-term results will further our understanding of this regimen’s efficacy in locally advanced BC. Clinical trial information: NCT02891161.
Annual change in forced oscillation technique correlates with FEV1 decline in patients with asthma, COPD, and asthma-COPD overlap
Authors: Yuko Tanaka, Keita Hirai, Hiromasa Nakayasu, Kanami Tamura, Toshihiro Masuda, Shingo Takahashi, Hirofumi Watanabe, Yutaro Kishimoto, Kyohei Oishi, Mika Saigusa, Taisuke Akamatsu, Akito Yamamoto, Satoru Morita, Kazuhiro Asada, Toshihiro Shirai
Journal: Journal of Allergy and Clinical Immunology (2020)
37P HER2 Tumor Heterogeneity and Discrepancies in HER2 Status Between Primary Tumor and Corresponding Circulating Tumor Cells in Metastatic Breast Cancer Patients
Authors: I. Migliaccio, F. Galardi, S. Bessi, G. Capaccioli, C. Biagioni, M. Truglia, L. Santarpia, A. Giannini, A. Di Leo, M. Pestrin
Journal: Annals of Oncology (2012)
Interaction between Early-Life Antibiotics Use and IL-13 Polymorphism in the Development of Atopic Dermatitis: COCOA Birth Cohort Study
Authors: Min Jee Park, So-Yeon Lee, Eun Sang Rhee, Sihyeon Lee, Mi-Jin Kang, Sungsu Jung, Dong In suh, Youn Ho Shin, Kyung Won Kim, Kangmo Ahn, Soo-Jong Hong
Journal: Journal of Allergy and Clinical Immunology (2020)